Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Prasugrel Hydrochloride

FDA-approved product (tablet, oral), marketed as Effient, Prasugrel, Prasugrel Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Prasugrel Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute coronary syndrome
  • Hemorrhage
  • Intermediate coronary syndrome
  • Myocardial infarction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Platelet aggregation inhibitors excl. heparin
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Prasugrel Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Prasugrel Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Prasugrel/Clopidogrel Maintenance Dose Washout Study

    NCT01014624 · start 2010-02

    Registered record
    Registry ID
    NCT01014624
    Conditions
    Coronary Artery Disease
    Interventions
    Prasugrel; Clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-02
    Completion
    2010-06
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionPrasugrel; Clopidogrel
    PhasePhase 4
    Registry statusCompleted

  • CYPRESS - CYPHER for Evaluating Sustained Safety

    NCT00954707 · start 2009-08

    Registered record
    Registry ID
    NCT00954707
    Conditions
    Coronary Artery Disease
    Interventions
    Clopidogrel & Aspirin, Prasugrel & Aspirin; Placebo & Aspirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2009-08
    Completion
    2016-03
    Enrolment
    2,509

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionClopidogrel & Aspirin, Prasugrel & Aspirin; Placebo & Aspirin
    PhasePhase 4
    Registry statusUnknown

  • A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects

    NCT00699998 · start 2008-06

    Registered record
    Registry ID
    NCT00699998
    Conditions
    Acute Coronary Syndrome
    Interventions
    Clopidogrel; Prasugrel; Commercially-available Aspirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-06
    Completion
    2012-04
    Enrolment
    9,326

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    InterventionClopidogrel; Prasugrel; Commercially-available Aspirin
    PhasePhase 3
    Registry statusCompleted

  • Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)

    NCT00642174 · start 2008-04

    Registered record
    Registry ID
    NCT00642174
    Conditions
    Diabetes Mellitus; Coronary Artery Disease
    Interventions
    prasugrel; Clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-04
    Completion
    2009-01
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus; Coronary Artery Disease
    Interventionprasugrel; Clopidogrel
    PhasePhase 2
    Registry statusCompleted

  • The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)

    NCT00385944 · start 2007-03

    Registered record
    Registry ID
    NCT00385944
    Conditions
    Acute Coronary Syndrome
    Interventions
    Prasugrel; Clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-03
    Completion
    2007-10
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    InterventionPrasugrel; Clopidogrel
    PhasePhase 2
    Registry statusCompleted